Inhibitory Role for Dual Specificity Phosphatase VHR in T Cell Antigen Receptor and CD28-induced Erk and Jnk Activation*

Andres Alonso, Manju SaxenaDagger, Scott Williams, and Tomas Mustelin§

From the Laboratory of Signal Transduction, La Jolla Cancer Research Center, The Burnham Institute, La Jolla, California 92037

Received for publication, July 20, 2000, and in revised form, November 14, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The 21-kDa dual specific protein phosphatase VH1-related (VHR) is one of the smallest known phosphatases, and its function has remained obscure. We report that this enzyme is expressed in lymphoid cells and is not induced by T cell antigen receptor like other dual specificity phosphatases. Introduction of exogenous VHR into Jurkat T cells caused a marked decrease in the transcriptional activation of a nuclear factor of activated T cells and an activator protein-1-driven reporter gene in response to ligation of T cell antigen receptors. The inhibition was dose-dependent and was similar at different doses of anti-receptor antibody. Catalytically inactive VHR mutants caused an increase in gene activation, suggesting a role for endogenous VHR in this response. In contrast, the activation of a nuclear factor kappa B-driven reporter was not affected. The inhibitory effects of VHR were also seen at the level of the mitogen-activated kinases Erk1, Erk2, Jnk1, Jnk2, and on reporter genes that directly depend on these kinases, namely Elk, c-Jun, and activator protein-1. In contrast, p38 kinase activation was not affected by VHR, and p38-assisted gene activation was less sensitive. Our results suggest that VHR is a negative regulator of the Erk and Jnk pathways in T cells and, therefore, may play a role in aspects of T lymphocyte physiology that depend on these kinases.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Members of the mitogen-activated protein kinase (MAP1 kinase) family are activated by a wide range of extracellular stimuli including growth and differentiation factors and cytokines as well as ultraviolet radiation, heat shock, and osmotic shock (reviewed in Refs. 1-3). Several distinct MAP kinase cascades have been identified in mammalian cells including the extracellular signal-regulated kinases Erk1 and Erk2, which preferentially transmit signals that regulate cell growth and differentiation, the c-Jun N-terminal kinases Jnk1 and Jnk2, the p38 kinases, which participate mainly in responses to stress, inflammation and apoptosis, and the 80-kDa Erk5, which may regulate cell proliferation (4). Activation of T lymphocytes by antigens is accompanied by activation of all of these pathways (5-8) although activation of the Jnks and p38s requires costimulation through CD28 (7), proinflammatory cytokines, or oxidative conditions that are often present at the site of inflammation and lymphocyte activation.

At the molecular level, MAP kinases are activated by a dual threonine and tyrosine phosphorylation within the motifs Thr-Glu-Tyr (Erk), Thr-Pro-Tyr (Jnk), or Thr-Gly-Tyr (p38) in their activation loops by a number of specific MAP kinase kinases (9). Conversely, inactivation of MAP kinases is achieved by dephosphorylation of either or both residues by protein Ser/Thr phosphatases, protein-tyrosine phosphatases, or dual specific protein phosphatases (DSPs) (reviewed in Refs.10-12). In fact, the number of identified phosphatases that inactivate MAP kinases exceeds the number of known MAP kinase kinases, providing the first example of an important process in which the regulatory emphasis is more on the phosphatases than on the kinases (11).

Many members of the DSP group have assumed a role in MAP kinase inactivation, and most are inducible nuclear proteins that play important negative feedback roles in cellular signaling processes in response to environmental signals such as mitogenesis, apoptosis, differentiation, and secretion of cytokines (10-12). The first cloned member of this group was the VH1 protein from the vaccinia virus (13). A closely related enzyme was subsequently found in mammalian cells and termed VHR (VH1-related) (14). Although most DSPs identified to date seem to be specific for Erk1 and Erk2, and a few prefer Jnk or p38, the cellular target(s) for VHR have remained unclear. VHR also differs from other DSPs in being much smaller, only 21 kDa.

We report that VHR is expressed in all examined lymphoid and hematopoietic cell types and is constitutively expressed in T cells. We also present evidence that VHR counteracts the Erk and Jnk MAP kinases, but not p38, and all reporter genes that depend on Erk or Jnk. As a catalytically inactive VHR behaved as a "dominant-negative" in many experiments, we suggest that this may be the physiological function of VHR in T lymphocytes.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Antibodies and Reagents-- The anti-VHR mAb was from Transduction Laboratories (Los Angeles, CA). The 12CA5 anti-hemagglutinin mAb was from Roche Molecular Biochemicals. The 9E10 hybridoma producing the mAb that recognizes the c-Myc epitope tag and the OKT3 hybridoma that produces the anti-CD3epsilon mAb were from American Type Culture Collection (Manassas, VA). Both mAbs were used as ascites. The mAb against CD28 was from PharMingen (San Diego, CA). The polyclonal anti-extracellular signal-regulated kinase 2 (Erk2) was from Santa Cruz Biotechnology Inc. A cDNA panel from hematopoietic and lymphoid organs was from CLONTECH (Palo Alto, CA).

Polymerase Chain Reactions and Plasmids-- The cDNA for VHR was amplified from a Jurkat cell cDNA library using the polymerase chain-reaction (PCR) primer pair 5'-A ATT GCT AGC ATG TCG GGC TCG TTC-3' and 5'-G CGC ATC GAT CTA GGG TTT CAA CTT-3' in a polymerase chain reaction using PWO polymerase obtained from Roche Molecular Biochemicals. The PCR product was sequenced and subcloned into the pEF/HA vector (15), which adds a hemagglutinin (HA) tag to the N terminus of the insert. The c-Myc-tagged Erk2 was in pEF-neo, the HA-tagged Erk1 (from G. Baier, University of Innsbruck, Austria) was in pEF-neo, HA-Jnk1 and HA-Jnk2 were in the pcDNA3 vector, and p38-alpha cDNA (from J. D. Lee, Scripps Clinic, La Jolla, CA) was subcloned into the pEF-HA vector. GAL4-Elk was from J. Tian and G. Hauser (Burnham Institute, La Jolla, CA), and GAL4-c-Jun and GAL4-luc were from T. Kawakami (La Jolla Institute for Allergy and Immunology, San Diego, CA).

Site-directed Mutagenesis-- To generate a catalytically inactive mutant of VHR, the codon for Cys-124 was changed into a codon for serine in the pEF/HA-VHR plasmid using the TransformerTM site-directed mutagenesis kit as recommended by the manufacturer (CLONTECH). The substrate-trapping mutant of VHR (VHR-D92A) was generated using the Quick Change (Stratagene, San Diego, CA) site-directed mutagenesis kit as instructed by the manufacturer. Both mutations were verified by nucleotide sequencing.

Cells and Transfections-- Jurkat T leukemia cells were kept at logarithmic growth in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, nonessential amino acids, and 100 units/ml each of penicillin G and streptomycin. These cells were transiently transfected with a total of 5-10 µg of DNA by electroporation at 950 microfarads and 240 V. Empty vector was added to control samples to make constant the amount of DNA in each sample. Cells were used for experiments 24 h after transfection. Human bone marrow was purchased from AllCells LLC (Foster City, CA). Bone marrow leukocytes were obtained by hypotonic lysis of the erythrocytes in water for 1 min followed by washing of the cells in RPMI medium. Peripheral blood lymphocytes (~80% T cells) were obtained from venous blood from healthy donors (Red Cross Blood Bank, San Diego, CA) by Ficoll gradient centrifugation and by removal of monocytes by adherence to plastic at 37 °C for 2 h. The adherent cells were also recovered.

Immunoprecipitation-- Cells were lysed in 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA containing 1% Nonidet P-40, 1 mM Na3VO4, 10 µg/ml aprotinin and leupeptin, 100 µg/ml soybean trypsin inhibitor and 1 mM phenylmethylsulfonyl fluoride and clarified by centrifugation at 15,000 rpm for 20 min. The clarified lysates were preabsorbed on protein G-Sepharose and then incubated with antibody for 2 h followed by protein G-Sepharose beads. Immune complexes were washed three times in lysis buffer, once in lysis buffer with 0.5 M NaCl, again in lysis buffer, and either suspended in SDS sample buffer or used for in vitro kinase assays.

Immunoblotting-- Proteins resolved by SDS-polyacrylamide gel electrophoresis were transferred electrophoretically to nitrocellulose filters, which were immunoblotted as before (15-19) with optimal dilutions of mAbs followed by anti-mouse-Ig peroxidase. The blots were developed by the enhanced chemiluminescence technique (ECL kit, Amersham Pharmacia Biotech) according to the manufacturer's instructions.

Jnk Assays-- These assays were performed as before (16). Briefly, 20 × 106 Jurkat T cells were transfected with either empty vector or 5 µg of HA-tagged Jnk1 or Jnk2 plasmid alone or plus 5 µg of VHR plasmid. Cells were harvested 2 days after electroporation, either left untreated or stimulated with anti-CD3epsilon mAb plus anti-CD28 (9.3) mAb followed by the cross-linking with anti-mouse Ig for 20 min at 37 °C, or UV-irradiated for 1 min at room temperature using a transilluminator (FBTI-88, lambda =312 nm; Fisher Scientific, Pittsburgh, PA). After irradiation, the cells were placed in a 37 °C incubator for 1 h before lysis. Cells were heat-shocked at 45 °C for 20 min.

Cells were lysed in 20 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM Na3VO4, 25 mM beta -glycerol phosphate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, leupeptin, and soybean trypsin inhibitor, and the HA-tagged Jnk was immunoprecipitated with 2 µg of anti-HA mAb (12CA5) as above. The kinase reaction was performed for 30 min at 30 °C in 20 µl of kinase buffer containing 25 mM HEPES, pH 7.5, 25 mM MgCl2, 25 mM beta -glycerol phosphate, 1 mM dithiothreitol, 0.1 mM Na3VO4, 10 µM cold ATP, 5 µg of GST-c-Jun, and 10 µCi of [gamma -32P]ATP. The reaction was terminated by adding 20 µl of 2 × SDS sample buffer and heating to 95 °C for 2 min. The samples were run on 10% SDS-polyacrylamide gels and transferred onto nitrocellulose filters, and the labeled proteins were visualized by autoradiography.

MAP Kinase Assays-- These were done as before (17-19). Briefly, 20 × 106 Jurkat T cells were transfected with 5 µg of c-Myc-tagged Erk2 plasmid and 5 µg of VHR plasmid. Empty vector was added to control samples to make constant the amount of DNA in each sample. Cells were harvested 2 days after electroporation, divided into two samples/transfection, and either stimulated with OKT3 (5 µg/ml) for 5 min at 37 °C or left untreated. Cells were lysed as described above, and the Myc-tagged Erk2 was immunoprecipitated with 2 µg of the 9E10 anti-Myc mAb followed by 25 µl of protein G-Sepharose beads. The kinase reaction was performed for 30 min at 30 °C in 20 µl of kinase buffer containing 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 20 mM MgCl2, 10 µg of myelin basic protein, 1 µM ATP, and 10 µCi of [gamma -32P]ATP. The reactions were terminated by adding 20 µl of 2 × SDS sample buffer and heating to 95 °C for 2 min. The samples were run on 12% SDS-polyacrylamide gels were transferred onto nitrocellulose filters, and the labeled proteins were visualized by autoradiography. The presence of equal amounts of the immunoprecipitated Erk2 was verified by immunoblotting using the anti-Erk2 antibody at 1:1000 dilution.

Luciferase Assays-- Luciferase assays were performed as described previously (16-19). Briefly, 20 × 106 cells were transfected with 2 µg of NFAT/AP-1-luc (or other reporters) together with empty pEF/HA vector alone or VHR plasmids. After stimulation for 6 h, the cells were lysed in 100 µl of 100 mM potassium phosphate, pH 7.8, 1 mM dithiothreitol, and 0.2% Triton X-100. The final assay contained 50 µl of lysate, 100 µl of ATP solution (10 mM ATP, 35 mM glycylglycine, pH 7.8, and 20 mM MgCl2), plus 100 µl of luciferin reagent (0.27 mM coenzyme A, 0.47 mM luciferin, 35 mM glycylglycine, pH 7.8, and 20 mM MgCl2). The activity was measured in an automatic luminometer (Monolight 2010, Analytical Luminescence Laboratory, Ann Arbor, MI). The activity of a cotransfected beta -galactosidase was measured and used to normalize the luciferase activity for transfection efficiency.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Expression of VHR in Hematopoietic and Lymphoid Cells-- To survey normal lymphoid cell types and organs for VHR expression, we designed an oligonucleotide primer pair complementary to the ends of the open reading frame to amplify VHR mRNA-derived sequences by the PCR from a panel of cDNA libraries (CLONTECH). A fragment of the expected size (558 base pairs) was readily obtained from bone marrow, fetal liver, lymph node, peripheral blood lymphocytes, spleen, thymus, tonsil, and the T leukemia cell line Jurkat (Fig. 1A). The expression was lowest in the thymus and highest in Jurkat. To verify that the amplification products were derived from VHR, we cloned and sequenced the fragment. The obtained sequence was 100% identical to the published sequence of VHR (14) (data not shown).



View larger version (51K):
[in this window]
[in a new window]
 
Fig. 1.   Expression of VHR in lymphoid cells. A, reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the expression of VHR mRNA in a panel of lymphoid tissues and cell types (1 ng of DNA/sample). The band at 558 base pairs in the upper panel is VHR, whereas the ~1-kilobase band in the lower panel is the housekeeping enzyme glycerol-3-phosphate dehydrogenase, a positive control. Right-hand panels are anti-VHR mAb immunoblots of lysates of the indicated cells (70 µg of protein/sample). B, anti-VHR immunoblot of immunoprecipitates obtained with anti-HA or anti-VHR mAbs as indicated from Jurkat T cells transfected with pEF-HA vector alone (lanes 1 and 2) or with HA-tagged VHR (lanes 3 and 4). C, anti-VHR immunoblot of Jurkat T cells incubated for the indicated times at 37 °C with medium alone (upper panel) or in the presence of 10 µg/ml anti-CD3epsilon mAb and anti-CD28 (lower panel). D, similar experiments with normal blood T lymphocytes. Note that the amount of VHR remains constant. PBL, peripheral blood lymphocytes, PBML, peripheral blood mononuclear leukocytes.

To confirm the presence of VHR protein in hematopoietic cells, cell lysate samples containing 70 µg of protein from isolated blood T cells, monocytes, bone marrow leukocytes, or Jurkat T cells were resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and immunoblotted with the anti-VHR mAb. An ~21-kDa band of very similar intensity was seen in these cells (Fig. 1A, right panels).

Generation of a HA-tagged VHR Expression Plasmid-- Next we subcloned the sequenced open reading frame of VHR into the pEF/HA vector, which adds an N-terminal HA tag to the insert. When the plasmid was transfected by electroporation into Jurkat T cells, a 23-kDa protein appeared as expected (the HA tag adds ~2 kDa). This protein was immunoprecipitated by both an anti-HA mAb and an anti-VHR mAb and was immunoblotted by both mAbs (Figs. 1 B and 2). In contrast, an endogenous protein of 21 kDa was immunoprecipitated and immunoblotted with only the anti-VHR mAb (Fig. 1, B and C).



View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of T cell antigen receptor-induced NFAT/AP-1 activation by VHR. A, activation of a luciferase reporter gene driven by NFAT/AP-1 (NFAT/AP-1 luc) at different doses of VHR plasmid. The data represent the mean from duplicate determinations in a representative of three independent experiments. The inset is an anti-HA blot to show expression of VHR in the transfectants (upper panel). B, activation of the same reporter in cells stimulated with different amounts of anti-CD3 mAb. The inset is an anti-HA blot of the same cells (upper panel). C, activation of the same reporter gene in cells cotransfected with 3 µg of the indicated VHR plasmids. The inset is an anti-HA blot of the same cells (upper panel). D, activation of the same reporter gene by phorbol ester and/or ionomycin as indicated. The inset is an anti-HA blot of the same cells (upper panel). PMA, phorbol 12-myristate 13-acetate. WT, wild type. E, activation of a nuclear factor kappa B-driven luciferase reporter gene (NF-kappa B luc) in cells cotransfected with the indicated amount of VHR plasmid. All luciferase activities are given as arbitrary light units (arb. units), generally 1/1000 of the luminometer readout values, and they were normalized for transfection efficiency using the activity of a cotransfected beta -galactosidase.

T Cell Activation Does Not Induce VHR Expression-- Because most DSPs are inducible genes encoded by immediate early genes, we wanted to determine whether this was also true for VHR. Jurkat T cells were treated with 5 µg/ml of the activating anti-CD3epsilon mAb OKT3 plus the anti-CD28 mAb for 0-48 h and then immunoblotted with the anti-VHR mAb. The amount of VHR immunoreactivity remained completely unchanged during these experiments (Fig. 1C). The same experiment was also performed with normal blood T cells with the same result (Fig. 1D). Thus, VHR is constitutively expressed in T cells prior to receptor stimulation and is not induced.

Active VHR Inhibits Anti-CD3 Plus Anti-CD28-induced Activation of a Reporter Gene Taken from the Interleukin-2 Gene-- As a rapid screening assay for a possible role of VHR in T cell activation, we coexpressed VHR with a sensitive luciferase reporter gene, in which luciferase transcription is under the control of a tandem NFAT/AP-1 element taken from the interleukin-2 gene promoter. This reporter responds to T cell antigen receptor ligation with anti-CD3epsilon mAbs alone or together with coligation of the CD28 costimulatory molecule. When these experiments were first performed with different amounts of VHR plasmid, we observed that VHR inhibited the response in a dose-dependent manner with a sharp drop in gene activation between 2 and 5 µg of plasmid (Fig. 2A). The expression of VHR protein correlated with the DNA dose (inset). A titration of the amount of anti-CD3epsilon showed that VHR did not shift the anti-CD3epsilon dose-response (e.g. by desensitizing the receptor) but inhibited it to an equal degree at all doses (Fig. 2B).

In contrast to the effect of catalytically active VHR, expression of the two catalytically inactive VHR mutants, C124S and D92A, had the opposite effect, namely a substantial increase in gene activation in response to anti-CD3epsilon or anti-CD3epsilon plus anti-CD28 (Fig. 2C). This dominant-negative effect may result from a displacement of endogenous, active VHR. If so, our results support the notion that endogenous VHR suppresses reporter gene activation. Catalytically active VHR also inhibited reporter gene activation induced by phorbol ester and ionomycin, whereas the inactive C124S mutant augmented it (Fig. 2D). In support of a role of VHR in the signaling pathways that up-regulate NFAT/AP-1-driven transcription, we found that coexpression of VHR with a luciferase reporter under the control of a nuclear factor kappa B element had a small stimulatory effect on its activation (Fig. 2E). Because nuclear factor kappa B induction, in contrast to NFAT/AP-1, was not inhibited in a dose-dependent manner, we conclude that VHR does not inhibit this pathway even when expressed at higher levels. The small stimulatory effect is of questionable significance but could be secondary to inhibition of other pathways.

Active VHR Inhibits Anti-CD3 Plus Anti-CD28-induced Activation of Jnk-- To further understand the effect of VHR on reporter gene activation and to address the hypothesis that VHR acts on one or several members of the MAP kinase family, we measured the activation of these kinases one by one. First, VHR was cotransfected with an epitope-tagged Jnk2 in Jurkat T cells. Two days after transfection, the cells were treated with anti-CD3epsilon plus anti-CD28 on ice for 15 min, washed twice with cold RPMI, and then incubated at 37 °C for 20 min in the presence of a cross-linking sheep anti-mouse Ig antibody. After cell lysis, the HA-tagged Jnk was immunoprecipitated with the 12CA5 anti-HA mAb and subjected to in vitro kinase assays using GST-c-Jun as a substrate. These experiments revealed that expression of active VHR inhibited the activation of Jnk, whereas the catalytically inactive mutant had little effect (Fig. 3, lanes 1-8). The amount of Jnk2 was found to be similar in all the samples (Fig. 3, lower panel), and the VHR proteins were equally expressed in lanes 5-8 (lower panel). This result was obtained in several independent experiments, and very similar results were obtained with Jnk1.



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of Jnk activation by VHR. In vitro kinase assays (upper panels) with GST-c-Jun N terminus as a substrate of HA-tagged Jnk2 immunoprecipitated from Jurkat T cells transfected with the indicated plasmids and treated with medium (odd lane numbers), anti-CD3e plus anti-CD28 (lanes 2, 4, 6, and 8), UV irradiation (lanes 10, 12, 14, and 16), or heat shock at 45 °C (lanes 18, 20, 22, and 24) for 20 min. The expressions of Jnk2 and VHR are shown by anti-HA immunoblots of lysates from the same transfectants (lower panels).

VHR Also Inhibits UV- and Heat Shock-induced Activation of Jnk-- Next we tested whether VHR would also affect stress-induced activation of Jnk2. Experiments were performed as above, but instead of stimulating the cells with antibodies, we either irradiated them with ultraviolet light or kept them at 45 °C for 20 min. Both treatments activated Jnk2, and both were inhibited by active VHR (Fig. 3, lanes 9-24). Activation of Jnk2 by heat shock was augmented ~2-fold by the catalytically inactive VHR mutant (39,203 cpm in lane 24 versus 17,333 cpm in lane 20 incorporated into the substrate), but the very strong activation of Jnk2 by ultraviolet light was partly reduced by this mutant. This finding was consistently seen in several independent experiments and may be due to binding to Jnk2 resulting in some steric hindrance of the kinase. The amount of Jnk2 was found to be similar in all the samples (lower panels), and VHR and VHR-C124S were equally expressed in lanes 13-16 and 21-24 (lower panels). These results were obtained in two independent experiments.

Inhibition of Erk Activation by Active VHR-- Having established that Jnk is sensitive to VHR, we tested Erk activation in similar experiments. A Myc-tagged Erk2 was coexpressed with VHR or inactive mutant VHR, and the cells were stimulated with the anti-CD3epsilon mAb for 5 min (anti-CD28 is not required). After cell lysis, Erk2 was immunoprecipitated with the 9E10 anti-Myc mAb and subjected to an in vitro kinase reaction with myelin basic protein as a substrate. These experiments revealed that Erk activation was reduced by active VHR but not by the inactive mutant (Fig. 4A). However, in most experiments, the inhibition was not as marked as the inhibition observed for Jnk. The amount of Erk was equal in all samples (Fig. 4A, middle panel), and VHR was well expressed (Fig. 4A, bottom panel). This result was obtained in several additional experiments.



View larger version (63K):
[in this window]
[in a new window]
 
Fig. 4.   VHR inhibits Erk activation but not p38 kinase activation. A, in vitro kinase assay with myelin basic protein (MBP) as a substrate of Myc-tagged Erk2 immunoprecipitated from Jurkat T cells transfected with the indicated plasmids and treated with medium (odd lane numbers) or anti-CD3epsilon mAb (even lane numbers) for 5 min. Equal amounts of Erk in the assay were verified by anti-Erk immunoblotting of the same filter (middle panel) and the expression of VHR by anti-HA immunoblotting of lysates from the same transfectants (lower panel). B, in vitro kinase assay (upper panel) with GST-ATF2 as a substrate of HA-tagged p38 immunoprecipitated from Jurkat T cells transfected with the indicated plasmids and treated with medium alone (odd lanes), UV irradiation (lanes 2, 4, 6, and 8), or anti-CD3epsilon (lanes 10, 12, 14, and 16) for 5 min. Equal expression was verified by anti-HA immunoblotting of lysates from the same transfectants (lower panel).

VHR Has No Effects on Receptor- or UV-induced Activation of p38 Kinase-- p38 kinase is also activated in T cells in response to receptor signaling and ultraviolet irradiation. However, coexpression of active or inactive VHR had no effect on these responses despite being well expressed (Fig. 4B). These results have been obtained in several independent experiments and suggest that VHR has specificity toward Jnk and Erk but not p38.

Effects of VHR on Downstream Targets for MAP Kinases-- To further investigate the negative regulation of Jnk and Erk by VHR, we decided to utilize a number of downstream targets of these kinases. In intact cells, many of these targets are also affected by p38, but the relative importance of the three principal MAP kinases varies considerably from target to target. First we utilized a luciferase reporter gene under the control of the Elk protein, which is phosphorylated and activated mostly by Erk. To increase or decrease its dependence on Erk, we coexpressed Erk, Jnk, or p38 with the reporter. These experiments showed that the reporter was sensitive to VHR and even more sensitive when the level of Erk was increased (Fig. 5A). Coexpression of p38 caused a smaller augmentation of reporter gene activation, and the inhibition was less striking, as would be expected if p38 were more involved relative to Erk in these cells. The effects of Jnk were intermediate.



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 5.   Inhibition of downstream targets for MAP kinases by VHR. A, activation of a luciferase reporter gene driven by Elk (Elk-GAL4-luc). The data represent the mean ± S.D. from triplicate determinations. The right-hand panels represent an anti-Erk2 blot (upper panel), a longer exposure of the anti-HA blot to show Jnk (middle panel), and a shorter exposure of the anti-HA blot to show p38 and VHR (lower panel) of the lysates of the transfectants. Note that endogenous Erk with a slightly lower Mr is visible in all lanes in the anti-Erk2 blot. B, activation of a c-Jun-induced luciferase reporter gene (c-Jun-GAL4 luc). The data represent the mean ± S.D. from triplicate determinations. The right-hand panel is an anti-HA blot to show Jnk and VHR. C, activation of a luciferase reporter gene driven by AP-1 (AP-1 luc). The data represent the mean ± S.D. from triplicate determinations. The right-hand panel is an anti-HA blot to show Jnk1, Erk1, and VHR.

The activation of the c-Jun protein is principally mediated by Jnk and can be measured using a c-Jun-GAL4 fusion protein, which controls the expression of a cotransfected GAL4-sensitive luciferase (20). This reporter was activated ~2-fold by stimulation of the T cells with anti-CD3epsilon plus anti-CD28 but was much augmented by coexpression of Jnk1 or Jnk2 (Fig. 5B). In both cases, a coexpressed VHR caused a strong inhibition of the reporter.

Finally we used a luciferase reporter gene driven by a single AP-1 site (without an adjacent NFAT element) that binds the dimeric Jun/Fos complex referred to as AP-1. This reporter was strongly induced when either Jnk or Erk was coexpressed, and in both cases VHR caused a marked inhibition of the response. In contrast to the Elk reporter, the AP-1 reporter was somewhat better responsive to Jnk and more inhibited by VHR in the presence of Jnk. Nevertheless, all these results show that both Erk and Jnk are similarly sensitive to inhibition by VHR, whereas p38 is much less so, if at all.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The 185-amino acid VHR was the first human DSP to be cloned (14); the enzyme has been crystallized, and its three-dimensional structure has been solved (21). The structure revealed that the catalytic center of VHR is composed of the same structural elements as in the classical protein-tyrosine phosphatases like PTP1B (22) including the cysteine (Cys-124) in the bottom of the catalytic cleft. Mutagenesis experiments and kinetic analyses have confirmed that Cys-124 is essential for catalysis (23, 24) and that Asp-92 participates in substrate dephosphorylation by acting as proton donor for the reaction (25). The dual specificity of VHR toward both phosphotyrosine and phosphoserine/phosphothreonine in protein substrates is explained by its catalytic pocket being less deep than in other protein-tyrosine phosphatases. This allows all three phosphoamino acid residues to reach the catalytic machinery (21). However, dephosphorylation of phosphotyrosine is much preferred over phosphothreonine and occurs much more rapidly (26).

Despite the detailed insights into its atomic structure and catalytic mechanism, the physiological function of VHR has remained obscure. It differs from the group of MAP kinase-specific DSPs in that it lacks noncatalytic regulatory or targeting regions. For this reason, the enzyme is also considerably smaller that other DSPs, only 21 kDa. Nevertheless, a recent paper (27) reported that VHR can dephosphorylate Erk1 and Erk2 and suggested that these two kinases are physiological targets for VHR. Our findings agree with this report, but we also find that Jnk is an equally preferred target for VHR in intact T cells. Like Todd et al. (27), we find that p38 kinase is not affected. It remains to be determined what gives VHR this specificity and how the enzyme is targeted and regulated.

In T cells, the Erk kinases are activated very rapidly with peak activities observed within minutes followed by a gradual decline beginning within 5 min and a return to basal or near basal levels at 10-30 min. The inducible DSPs, primarily the Pac-1 protein in lymphocytes (28), are not present at these time points but appear in the nucleus some 30-60 min after cell stimulation. In this location, they can dephosphorylate any remaining activated MAP kinases and terminate the response. In fibroblasts lacking MKP-1 (29), also encoded by an immediate early gene (30), the activation of MAP kinase also proceeds normally. In contrast, when MKP-1 is expressed in cells under a noninducible promoter, it strongly blocks MAP kinase activation by active Ras (31) or by extracellular stimuli (30, 32, 33). At the early time points, however, MAP kinase activation must be counteracted by phosphatases that are present in resting cells such as hematopoietic protein-tyrosine phosphatases (17, 18) and VHR. At present, no other MAP kinase-specific phosphatases are known to be constitutively expressed in lymphocytes.

In its role as a negative regulator of Erk, VHR may be competing with a number of other phosphatases (reviewed in Ref. 11). However, as a Jnk regulator VHR is accompanied only by VH5 (M3/6 in the mouse (34)) and perhaps by MKP-2, which dephosphorylates both Erk and Jnk with comparable efficiency at least in vitro (35). Both of these enzymes are inducible nuclear enzymes that may not be present in T cells at least during the first 30-60 min after receptor stimulation. Thus, VHR may be of particular importance in this cell type as a negative regulator of Jnk1 and Jnk2, which are important signal transducers in lymphocytes as well as other cell types (36, 37).


    ACKNOWLEDGEMENTS

We are grateful to Drs. Gottfried Baier, J. D. Lee, Jianmin Tian, Greg Hauser, and Toshiaki Kawakami for the kind gift of reagents.


    FOOTNOTES

* This work was supported by a fellowship from the Spanish Ministries of Education and Culture and by Grants AI48032, AI35603, AI41481, and AI40552 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Current address: Gemini Science Inc., 10355 Science Center Dr., San Diego, CA 92121.

§ To whom correspondence should be addressed: Laboratory of Signal Transduction, La Jolla Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037. Tel.: 858-713-6270; E-mail: tmustelin@burnhman-inst.org.

Published, JBC Papers in Press, November 20, 2000, DOI 10.1074/jbc.M006497200


    ABBREVIATIONS

The abbreviations used are: MAP kinase, mitogen-activated protein kinase; NFAT, nuclear factor of activated T cells; AP-1, activator protein-1; Erk, extracellular signal-regulated protein kinase; Jnk, c-Jun N-terminal kinase; AP-1, activator protein-1; DSP, dual specific protein phosphatase; VHR, VH1-related; mAb, monoclonal antibody; PCR, polymerase chain reaction; HA, hemagglutinin; GST, glutathione S-transferase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Kyriakis, J. M., and Avruch, J. (1996) J. Biol. Chem. 271, 24313-24316[Free Full Text]
2. Robinson, M. J., and Cobb, M. H. (1997) Curr. Opin. Cell Biol. 9, 180-186[CrossRef][Medline] [Order article via Infotrieve]
3. Schaeffer, H. J., and Weber, M. J. (1999) Mol. Cell. Biol 19, 2435-2441[Free Full Text]
4. Kato, Y., Kravchenko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J., and Lee, J. D. (1997) EMBO J. 16, 7054-7066[Abstract/Free Full Text]
5. Nel, A. E., Hanekom, C., Rheeder, A., Williams, K., Pollack, S., Katz, R., and Landreth, G. (1990) J. Immunol. 144, 2683-2689[Abstract/Free Full Text]
6. Whitehurst, C. E., and Geppert, T. D. (1996) J. Immunol. 156, 1020-1029[Abstract]
7. Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., and Ben-Neriah, Y. (1994) Cell 77, 727-736[Medline] [Order article via Infotrieve]
8. Salmon, R. A., Foltz, I. N., Young, P. R., and Schrader, J. W. (1997) J. Immunol. 159, 5309-5317[Abstract]
9. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H., and Goldsmith, E. J. (1997) Cell 90, 859-869[Medline] [Order article via Infotrieve]
10. Keyse, S. M. (2000) Curr. Opin. Cell Biol. 12, 186-192[CrossRef][Medline] [Order article via Infotrieve]
11. Saxena, M., and Mustelin, T. (2000) Semin. Immunol. 12, 387-396[CrossRef][Medline] [Order article via Infotrieve]
12. Camps, M., Nichols, A., and Arkinstall, S. (1999) FASEB J. 14, 6-16[Abstract/Free Full Text]
13. Guan, K. L., Bryoles, S. S., and Dixon, J. E. (1991) Nature 350, 359-362[CrossRef][Medline] [Order article via Infotrieve]
14. Ishibashi, T., Bottaro, D. P., Chan, A., Kiki, T., and Aaronson, S. A (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 12170-12174[Abstract]
15. von Willebrand, M., Jascur, T., Bonnefoy-Bérard, N., Yano, H., Altman, A., Matsuda, Y., and Mustelin, T. (1996) Eur. J. Biochem. 235, 828-835[Abstract]
16. Gjörloff-Wingren, A., Saxena, M., Williams, S., Hammi, D., and Mustelin, T. (1999) Eur. J. Immunol. 29, 3845-3854[CrossRef][Medline] [Order article via Infotrieve]
17. Saxena, M., Williams, S., Brockdorff, J., Gilman, J., and Mustelin, T. (1999) J. Biol. Chem. 274, 11693-11700[Abstract/Free Full Text]
18. Saxena, M., Williams, S., Taskén, K., and Mustelin, T. (1999) Nat. Cell Biol. 1, 305-311[CrossRef][Medline] [Order article via Infotrieve]
19. Jascur, T., Gilman, J., and Mustelin, T. (1997) J. Biol. Chem. 272, 14483-14488[Abstract/Free Full Text]
20. Hata, D., Kitaura, J., Hartman, S. E., Kawakami, Y., Yokota, T., and Kawakami, T. (1998) J. Biol. Chem 273, 10979-10987[Abstract/Free Full Text]
21. Yuvaniyama, J., Denu, J. M., Dixon, J. E., and Saper, M. A. (1996) Science 272, 1328-1331[Abstract]
22. Barford, D., Flint, A. J., and Tonks, N. K. (1994) Science 263, 1397-1404[Medline] [Order article via Infotrieve]
23. Zhou, G., Denu, J. M., Wu, L., and Dixon, J. E. (1994) J. Biol. Chem. 269, 28084-28090[Abstract/Free Full Text]
24. Denu, J. M., and Dixon, J. E. (1995) Proc. Natl. Acad. Sci. U. S. A 92, 5910-5914[Abstract/Free Full Text]
25. Denu, J. M., Zhou, G., Guo, Y., and Dixon, J. E. (1995) Biochemistry 34, 3396-3403[Medline] [Order article via Infotrieve]
26. Denu, J. M., Zhou, G., Wu, L., Zhao, R., Yuvaniyama, J., Saper, M. A., and Dixon, J. E. (1995) J. Biol. Chem. 270, 3796-3803[Abstract/Free Full Text]
27. Todd, J., Tanner, K., and Dent, J. (1999) J. Biol. Chem. 19, 13271-13280[CrossRef]
28. Rohan, P. J., Davis, P., Moskaluk, C. A., Kearns, M., Krutzsch, H., Siewbenlist, U., and Kelly, K. (1993) Science 259, 1763-1766[Medline] [Order article via Infotrieve]
29. Dorfman, K., Carrasco, D., Gruda, M., Ryan, C., Lira, S. A., and Bravo, R. (1996) Oncogene 13, 925-931[Medline] [Order article via Infotrieve]
30. Charles, C. H., Sun, H., Lau, L. F., and Tonks, N. K. (1993) Proc. Natl. Acad. Sci. U. S. A 90, 5292-5296[Abstract]
31. Sun, H., Tonks, N. K., and Bar-Sagi, D. (1994) Science 266, 285-288[Medline] [Order article via Infotrieve]
32. Sun, H., Charles, C. H., Lau, L. F., and Tonks, N. K. (1994) Cell 75, 487-493
33. Noguchi, T., Metz, R., Chen, L., Mattei, M. G., Carrasco, D., and Bravo, R. (1993) Mol. Cell. Biol. 13, 5195-5205[Abstract]
34. Muda, M., Theodosiou, A., Rodrigues, N., Boschert, U., Camps, M., Gillieron, C., Davies, K., Ashworth, A., and Arkinstall, S. (1996) J. Biol. Chem. 271, 27205-27208[Abstract/Free Full Text]
35. King, A. G., Ozanne, B. W., Smythe, C., and Ashworth, A. (1995) Oncogene 11, 2553-2563[Medline] [Order article via Infotrieve]
36. Sabapathy, K., Hu, Y., Kallunki, T., Schreiber, M., David, J. P., Jochum, W., Wagner, E. F., and Karin, M. (1999) Curr. Biol. 9, 116-125[CrossRef][Medline] [Order article via Infotrieve]
37. Chu, W. M., Ostertag, D., Li, Z. W., Chang, L., Chen, Y., Hu, Y., Williams, B., Perrault, J., and Karin, M. (1999) Immunity 11, 721-731[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.